COLL 29.96 Stock Price Collegium Pharmaceutical, Inc.
Range: | 25.16-42.287 | Vol Avg: | 399248 | Last Div: | 0 | Changes: | -0.45 |
Beta: | 0.95 | Cap: | 0.97B | Currency: | USD | Exchange: | NASDAQ |
Sector: | Healthcare | IPO: | Thu May 07 2015 | Empoloyees: | 197 |
CUSIP: | 19459J104 | CIK: | 0001267565 | ISIN: | US19459J1043 | Country: | US |
CEO: | Mr. Vikram Karnani | Website: | https://www.collegiumpharma.com |
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.